Pharmaceutical Manufacturing & Development (Women's Health)
Strategic Profile
The company's lead product candidate is Twirla, a once-weekly contraceptive patch. Following the acquisition, Agile combined with Insud Pharma's US subsidiary, Exeltis USA, Inc., expanding their women's health and contraceptive portfolio. Agile now operates as an indirect subsidiary of Insud and has ceased to be listed on any public market.
Cyborg Score Rationale
The company was acquired in August 2024 at a relatively modest valuation ($45M), indicating limited commercial success or market traction. While Twirla represents a differentiated women's health product, the company struggled to maintain independent viability in a competitive pharma landscape dominated by larger players.
Top Insights
(August 2024) Acquired by Spain-based Insud Pharma for $45M enterprise value, ending public status
Twirla—once-weekly transdermal contraceptive patch—represents alternative to oral contraceptives but faced commercialization headwinds
Company pivoted from NASDAQ to OTCQB pre-acquisition, reflecting declining market cap and investor confidence
Integration with Insud's Exeltis USA subsidiary positions Twirla within larger women's health portfolio under foreign pharmaceutical ownership
Named Competitors
Xulane — Weekly contraceptive patch
Yaz — Oral hormonal contraceptive
Ortho-Cyclen — Oral hormonal contraceptive
Recent Developments
(August 2024) Acquisition completed by Insud Pharma, S.L.; company delisted from OTC markets and became private subsidiary
(June 2024) Merger agreement signed with Insud Pharma
(Prior to 2024) Twirla regulatory pathway faced delays; company shifted from NASDAQ to over-the-counter trading
Open the full interactive Agile Therapeutics Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.